<DOC>
	<DOCNO>NCT02048072</DOCNO>
	<brief_summary>This study design primarily evaluate impact Gilenya ( Fingolimod ) autonomic nervous system patient treat first time Gilenya ( Fingolimod ) . Effects cardiovascular system study well . The study conduct answer question , , yes , impact treatment Gilenya ( Fingolimod ) autonomic nervous system . To knowledge little known effect Gilenya ( Fingolimod ) autonomic nervous system . We know rare , potentially clinically therapeutically relevant cardiovascular adverse event Gilenya ( Fingolimod ) . From scientific point view mechanisms mediate interest . Maybe well understanding mechanism might even clinical relevance ( e.g . risk stratification ) . The impact Gilenya ( Fingolimod ) autonomic nervous system quantitavely measure , use state-of-the-art technique . Non-invasive blood pressure measurement perform Finometer Pro ( Finapres Medical Systems , NL ) different paradigm ( breathe rest , deep breath , valsalva maneuver , active standing ) . In addition sympathetic skin reaction perform . The non-invasive blood pressure measurement do continuous , plethysmographic blood pressure measurement index finger , patient perform task mention . By interpret blood pressure curve , heart rate blood pressure variability calculate . The sympathetic skin reaction consist measure change electric conductibility skin ( palms sol ) electric stimulus peripheral nerve . These parameter allow assess functionality four important autonomic functional system ( orthostasis , sympathetic adrenergic , sympathetic cholinergic , parasympathetic cholinergic ) . Normative data acquire lab . Our hypothethis , change heart rate variability t4,5h compare baseline ( t0 ) parameter `` RMSSD '' `` normal breathing '' .</brief_summary>
	<brief_title>Evaluation Autonomic Nervous System During First-dosing With 0.5mg Fingolimod ( Gilenya ) Patients With Relapsing-remitting MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>indication treatment Gilenya accord label treatment Gilenya intend contraindication treatment Gilanya safetyaspects fullfilled age 18 60 year write consent give relapse last 30 day befor randomization steroid within 30 day randomization heart rhythm disturbance new currently change dose ( last 4 week ) batablockers , calcium antagonist , antidepressant antiarrhythmics diabetes mellitus polyneuropathy miss consent pregnancy lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>relapse remit</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>fingolimod</keyword>
	<keyword>Gilenya</keyword>
	<keyword>autonomic nervous system</keyword>
</DOC>